MRNA research enabled the remarkably fast production of COVID-19 vaccine candidates in the pandemic ... defending the body ...

Allen Institute scientists are learning why vaccines can trigger a weaker response in older adults, around age 65, and what ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

The study, published in the journal Nature, showed the jabs provided an immunity boost that helped extend survival for certain skin and lung cancers.

Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed withour AI-Immunology™ ...

Recognized in the Biotechnology category of the 2025 Top Innovations contest, small Cas12l nucleases are versatile, ...

Jason McLellan (Hopkins BCMB Ph.D. ‘09), a professor of molecular biosciences and the Welch Chair in Chemistry at The ...